US20030013888A1 - Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid - Google Patents
Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid Download PDFInfo
- Publication number
- US20030013888A1 US20030013888A1 US09/870,942 US87094201A US2003013888A1 US 20030013888 A1 US20030013888 A1 US 20030013888A1 US 87094201 A US87094201 A US 87094201A US 2003013888 A1 US2003013888 A1 US 2003013888A1
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- aryloyloxy
- alkenoyloxy
- alkynoyloxy
- taxol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 29
- 238000002360 preparation method Methods 0.000 title claims description 12
- ZOEOTARZBSSYGP-UHFFFAOYSA-N OC(=O)C1CNC(=C=O)O1 Chemical compound OC(=O)C1CNC(=C=O)O1 ZOEOTARZBSSYGP-UHFFFAOYSA-N 0.000 title claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 63
- 239000001257 hydrogen Substances 0.000 claims abstract description 63
- 125000003118 aryl group Chemical group 0.000 claims abstract description 32
- -1 alkeyloxy Chemical group 0.000 claims abstract description 31
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 30
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 26
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 12
- 125000004104 aryloxy group Chemical group 0.000 claims abstract description 10
- 125000005133 alkynyloxy group Chemical group 0.000 claims abstract description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims abstract description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 39
- 229930012538 Paclitaxel Natural products 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 229960001592 paclitaxel Drugs 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 150000002431 hydrogen Chemical group 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000000543 intermediate Substances 0.000 claims description 11
- KNWCDYSKJSREAQ-UHFFFAOYSA-N 1,3-oxazolidine-2-carboxylic acid Chemical compound OC(=O)C1NCCO1 KNWCDYSKJSREAQ-UHFFFAOYSA-N 0.000 claims description 10
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 229940123237 Taxane Drugs 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 8
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims description 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000000466 oxiranyl group Chemical group 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 150000004579 taxol derivatives Chemical class 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 125000003368 amide group Chemical group 0.000 claims description 3
- VBQDSLGFSUGBBE-UHFFFAOYSA-N benzyl(triethyl)azanium Chemical group CC[N+](CC)(CC)CC1=CC=CC=C1 VBQDSLGFSUGBBE-UHFFFAOYSA-N 0.000 claims description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 238000005886 esterification reaction Methods 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 2
- 125000006038 hexenyl group Chemical group 0.000 claims description 2
- 125000005980 hexynyl group Chemical group 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 claims description 2
- 125000005981 pentynyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- YLTKUYGTOCGZEZ-UHFFFAOYSA-N 2-hydroxy-3-isocyanatopropanoic acid Chemical compound OC(=O)C(O)CN=C=O YLTKUYGTOCGZEZ-UHFFFAOYSA-N 0.000 claims 2
- 238000010931 ester hydrolysis Methods 0.000 claims 2
- ANOVYEUPYUXCEO-UHFFFAOYSA-N 2,2-dimethyl-3-prop-2-ynoxycarbonyl-1,3-oxazolidine-5-carboxylic acid Chemical compound CC1(C)OC(C(O)=O)CN1C(=O)OCC#C ANOVYEUPYUXCEO-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 0 [1*]C#C[C@]([2*])([3*])OC(=O)N1C([4*])C(C(=O)O)OC1([5*])[6*] Chemical compound [1*]C#C[C@]([2*])([3*])OC(=O)N1C([4*])C(C(=O)O)OC1([5*])[6*] 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical group [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 229930190007 Baccatin Natural products 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- IUPYBTXEPWEUSK-UHFFFAOYSA-N 2,2-dimethyl-4-phenyl-3-prop-2-ynoxycarbonyl-1,3-oxazolidine-5-carboxylic acid Chemical compound C#CCOC(=O)N1C(C)(C)OC(C(O)=O)C1C1=CC=CC=C1 IUPYBTXEPWEUSK-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YOWQWFMSQCOSBA-UHFFFAOYSA-N 2-methoxypropene Chemical compound COC(C)=C YOWQWFMSQCOSBA-UHFFFAOYSA-N 0.000 description 3
- HOJZAHQWDXAPDJ-UHFFFAOYSA-N 3-anilino-2-hydroxypropanoic acid Chemical class OC(=O)C(O)CNC1=CC=CC=C1 HOJZAHQWDXAPDJ-UHFFFAOYSA-N 0.000 description 3
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- XXRMWTWYBZRJCB-UHFFFAOYSA-N oxetane Chemical compound C1COC1.C1COC1 XXRMWTWYBZRJCB-UHFFFAOYSA-N 0.000 description 2
- RAMTXCRMKBFPRG-UHFFFAOYSA-N prop-2-ynyl carbonochloridate Chemical group ClC(=O)OCC#C RAMTXCRMKBFPRG-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical group C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- VNCGNFQIEYLCSC-UHFFFAOYSA-N 2,2,2-trichloroethoxy carbonochloridate Chemical compound ClC(=O)OOCC(Cl)(Cl)Cl VNCGNFQIEYLCSC-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- LZJZHDQLRPECOE-UHFFFAOYSA-N 3-(n-benzoylanilino)-2-hydroxypropanoic acid Chemical group C=1C=CC=CC=1N(CC(O)C(O)=O)C(=O)C1=CC=CC=C1 LZJZHDQLRPECOE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- FZLSDZZNPXXBBB-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1 FZLSDZZNPXXBBB-KDURUIRLSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ONZCKWZUZHURAJ-CFXKIKLCSA-N C#CCOC(=O)N1[C@@H](C)[C@H](C(=O)O)OC1(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](O)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](OC(=O)[C@@H]4OC(C)(C)N(C(=O)OCC#C)[C@H]4C)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@H](C)N)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C Chemical compound C#CCOC(=O)N1[C@@H](C)[C@H](C(=O)O)OC1(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](O)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](OC(=O)[C@@H]4OC(C)(C)N(C(=O)OCC#C)[C@H]4C)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C.[H][C@]12[C@H](C)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@H](C)N)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12O[Ac])C3(C)C ONZCKWZUZHURAJ-CFXKIKLCSA-N 0.000 description 1
- ZUHYQDJUEUPTHV-GGHKMYOPSA-N C#CCOC(=O)N1[C@@H](C2=CC=CC=C2)[C@H](C(=O)O)OC1(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](O)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@@H]4OC(C)(C)N(C(=O)OCC#C)[C@H]4C4=CC=CC=C4)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](N)C4=CC=CC=C4)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C Chemical compound C#CCOC(=O)N1[C@@H](C2=CC=CC=C2)[C@H](C(=O)O)OC1(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](O)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@@H]4OC(C)(C)N(C(=O)OCC#C)[C@H]4C4=CC=CC=C4)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C.[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](N)C4=CC=CC=C4)C(C)=C([C@@H](C)C(=O)[C@]1(C)[C@@H](C)C[C@H]1OC[C@]12OC(C)=O)C3(C)C ZUHYQDJUEUPTHV-GGHKMYOPSA-N 0.000 description 1
- SQMRKRGWAKRETE-XHNFMJJRSA-N C[C@@H](C1=CC=CC=C1)[C@@H](O)C=O.O=C[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C[C@@H](C1=CC=CC=C1)[C@@H](O)C=O.O=C[C@H](O)[C@@H](NC(=O)C1=CC=CC=C1)C1=CC=CC=C1 SQMRKRGWAKRETE-XHNFMJJRSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Definitions
- the present invention relates to a novel oxazolidine carboxylic acid and a process for its preparation.
- the invention further relates to a process for the preparaton of paclitaxel (taxol) using such oxazolidine carboxylic acid.
- Paclitaxel (Taxol) (1) is a terpene of taxane family and has the formula shown below and has an application for treatment of various types of cancer.
- Non-natural analog of paclitaxel (taxol), docetaxel (taxotere) (2) is also an approved anticancer drug.
- paclitaxel has two distinct unts.
- One is baccatin (3) and other is N-benzoylphenylisoserine, the side chain, connected to baccatin at C-13 through ester linkage. It has been shown that the -amido- -hydroxy ester side chain at C-13 is very essential for anticancer activity of taxol and any other taxol analogs.
- 10-deacetyl baccatin (4) is more readily available than taxol from the leaves of yew tree and comprises a starting material for semisynthesis of taxol and taxol analogs.
- An object of this invention is to propose a novel oxazolidine carboxylic acid and a process for the preparation thereof.
- Another object of this invention is to propose oxazolidine carboxylic acid which can advantageously be used in the preparation of anticancer drugs.
- Still another object of this invention is to propose a process for the preparation of taxol and its synthetic analogs using the proposed oxazolidine carboxylic acid.
- the present invention is directed to 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid and its analogs having a formula
- R 1 is hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, R 2 and R 3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl;
- R is hydrogen, alkyl, alkenyl, alkynyl, aryl, substituted aryl, heteroaryl.
- R 5 and R 6 independently selected from hydrogen, alkyl, alkenyl, alkynyl, arly, heteroaryl, alkoxy, alkeyloxy, alkynyloxy, aryloxy, heteroaryloxy.
- the oxazoldine alkyl groups either alone or with the variable substituents defined above are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like.
- the alkyl part of alkoxy groups defined above are same as a alkyl groups.
- the oxazoldine alkenyl groups either alone or with the various substituents defined above are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, and the like.
- the alkenyl part of alkenyloxy groups defined above are same as a alkenyl groups.
- the oxazoldine alknyl groups are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl and the like.
- the alkynyl part of alkynyloxy groups defined above are same as alkynyl groups.
- the oxazoldine aryl moieties eiher alone or with various substituents contain from 6 to 10 carbon atoms and include pheny, -naphthyl etc. substituents include alkanoxy, hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino; amido etc.
- aryloxy includes aromatic heterocyclic moieties
- aryl includes any compound having an aromatic ring of which no hetero atom is a member
- heteroaryl includes any compound having an aromatic ring which comprises a hetero atom
- the oxazolidine carboxylic acid has a formula wherein R 1 , R 2 and R 3 are hydrogen, R 4 is phenyl and R 5 and R 6 are methyl.
- the present invention also describes process of preparation of 3-(alk-2-ynyloxy)carbonyl-5-oxazolidine carboxylic acid and its analogs.
- a and B are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy aryloyloxy or;
- L and D are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy;
- E and F are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy aryloyloxy; or E and F together form an oxo;
- G is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or;
- G and M together form an oxo or methylene or oxirane ring or
- M and F together form an oxetane ring
- J is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or
- I is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy; or
- K is hydrogen or hydroxy, lower alkoxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy
- P and Q are independently hydrogen or hydroxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy or P and Q together form an oxo;
- S and T are independently hydrogen, lower alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, substituted aryl or substituted aryloxy;
- U and V are independently hydrogen or lower alkyl, alkenyl, alkynyl, aryl or substituted aryl or heteroaryl and
- W and W′ are independently hydrogen or lower alkyl, aryl or substituted aryl
- Y is hydrogen or lower alkyl, aryl or substituted aryl.
- the present invention also describes the preparation of taxol intermediates, natural taxol and non-natural occurring taxols of following structural formula:
- a and B are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, or;
- L and D are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy;
- E and F are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy; or E and F together form an oxo;
- G is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or;
- G and M together form an oxo or methylene or oxirane ring or M and F together form an oxetane ring;
- J is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or
- I is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy; or
- K is hydrogen or hydroxy, lower alkoxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy
- P and Q are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy or alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy
- S and T are independently hydroxy, alkoxy, aryloxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy;
- U and V are independently hydrogen or lower alkyl, alkenyl, alkynyl, aryl or substituted aryl or heteroaryl and
- W is hydrogen, alkanoyl, alkenoyl, alkynoyl, aryloyl, heteroaryloyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl.
- the taxol alkyl groups either alone or with the variable substituents defined above are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like.
- the taxol -alkenyl groups either alone or with the various substituents defined above are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl hexenyl, and the like.
- the taxol alkynyl groups are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethynyl, propynyl, butynyl, isobutynyl, pentynyl hexynyl and the like.
- Exemplary alkanoyloxy include acetate, propionate, butyrate, valarate, isobutyrate and the like, the more preferred alkanoyloxy is acetate.
- the taxol aryl moieties either alone or with various substituents contain from 6 to 10 carbon atoms and include phenyl, -naphthyl etc. Substituents include alkanoxy, hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino; amido etc. phenyl is the more preferred aryl.
- aryloyloxy includes aromatic heterocyclic moieties
- aryl includes any compound having an aromatic ring of which no hetero atom is a member
- heteroaryl includes any compound having an aromatic ring which comprises a hetero atom.
- reaction 1 3-(alk-2-ynyloxy)carbonyl-5-oxazolidine carboxylic acid. The process is illustrated in reaction 1:
- isoserine 12 is the starting material.
- R is aryl and the most preferred R is phenyl.
- the arylisoserine has two asymmetric carbons, all optically active forms such as enantiomers, diastereomers, racemic mixtures and other mixtures are contemplated here.
- the preferred optically active form of pheneylisoserine is 2R, 3S. This phenylisoserine is commercially available.
- alk-2-ynyl groups are preferably lower alk-2-ynyl containing from three to six carbon atoms in the principal chain and up to 10 carbon atoms and include but-2-ynyl, pent-2-ynyl, prop-2 ynyl, hex-2-ynyl and the like.
- haloformate is prop-2-ynyl chloroformate which is available commercially. This can be prepared from diphosgene/triphosgene and propargyl alcohol following the procedure given in Helv.Chim.Acta. Vol 77, 561, 1994.
- the most preferred base here is sodium bicarbonate.
- the condensation is carried out by addition of chloroformate into a solution of isoserine in aqueous bicarbonate over a period of 5-30 min, most preferably over 10-15 min.
- the acidification of the reaction mixture affords the N-(alk -2-ynyloxy)carbonylisoserine 13.
- R 1 is phenyl
- R 2 , R 3 , and R 4 are hydrogen.
- N-(Alk-2-ynyloxy)carbonylisoserine is then converted into corresponding ester in presence of an alcohol and an activating agent such as dicyclohexylcarbodiimide or carbonyldiimidazole.
- an activating agent such as dicyclohexylcarbodiimide or carbonyldiimidazole.
- the most preferred alcohol is methanol and the most preferred activating agents is carbonyldiimidazole.
- the esterification can be carried out in various solvents such as dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, acetonitrile or dimethylformamide.
- the most preferred solvent is acetonitrile.
- the esterification is carried out by first mixing acid with activating agent for 0.5-6 hr, most preferably for 1 hr, at 0-25° C., most preferably at 10° C. Then the alcohol is introduced in the mixture over a period of 10-60 min, most preferably over 30 min and the mixing is done for 1-6 hr, most preferably for 2 hr.
- Methyl ester is alternatively prepared by condensing isoserine with diazomethane.
- the ethereal solution of diazomethane is prepared from following the standard procedure described in Vogel's Text book of Practical Organic Chemistry, 1989, page 432.
- the methylation is effected by mixing the solution of N -(alk-2-ynyloxy)carbonylisoserine in tetrahydrofuran with excess ethereal solution of diazomethane.
- the resultant mixture is stored for 1-6 hr, most preferably for 2 hr at 5-25° C., most preferably at 10° C., for complete reaction.
- R 1 is phenyl
- R 2 , R 3 and R 4 are hydrogen
- R is methyl
- N-(alk-2-ynyloxy) carbonylisoserine ester 14 is converted into oxazolidine 15 in presence of chemical such as alkoxyalkene or gem-dialkoxyalkane or 1,1,1-trialkoxyalkane.
- chemical such as alkoxyalkene or gem-dialkoxyalkane or 1,1,1-trialkoxyalkane.
- These chemicals are basically reagents for protection of vicinal functional groups such as diols or amino/amidoalchohols in cyclic form.
- the appropriate chemical is chosen on the basis of type of protecting group required.
- the most preferred alkoxylalkene, 2-methoxypropene, is available commercially.
- the reactions are catalysed by p-arylsulfonic acid or their pyridinium salt.
- the most preferred catalyst is pyridinium p-toluenesulfonate.
- the protection with 2-methoxypropene results in formation of 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic ester 15.
- R 1 , R 2 and R 3 are hydrogen, R 4 is phenyl; R 5 , R 6 and R 7 are methyl.
- 3-(Alk-2-ynyloxy) carbonyl-5oxazolidine carboxylic ester is finally converted into corresponding acid by hydrolysis with alkali hydroxide or carbonate and mineral acid used successively.
- the hydrolysis is effected by mixing of a solution of ester in alcohol with an Aq. alkali hydroxide.
- the most preferred alcohol is methanol and the most preferred alkali hydroxide is sodium hydroxide.
- the mixing is done for 1 to 6 hr, the most preferably for 3 hr.
- the reaction mixture is acidified to pH 3-6, most preferably 4.5.
- the acid 16 is isolated by extraction with dichloromethane.
- R 1 , R 2 , and R 3 are hydrogen
- R 4 is phenyl
- R 5 and R 6 are methyl.
- 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic is 3-(prop-2-ynyloxy) carbonyl-2,2-di methyl-4-phenyl-5-oxazolidine carboxylic acid.
- the preferred tetracyclic taxane alcohols are 7-O-triethylsilylbaccatin, 7-O-(2,2,2-trichloro-ethoxy) carbonylbaccatin, 7,10-di-O-(2,2,2-trichloroethoxy) carbonyl-10-deacetylbaccatin, 7, 10-di-O-benzyloxycarbonyl-10-deacetyl baccatin, 7-O-t-butyloxycarbonylbaccatin, 7, 10-di-O-t-butyloxycarbonyl-10-deacetylbaccatin, 7-O-(prop-2-ynyloxy) carbonyl baccatin, and 7,10-di-O-(prop-2-ynyloxy) carbonyl-10-deacetyl baccatin.
- the most preferred alcohols are 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin, 7,10-di-O-(
- 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin, 7,10-di-O-(2,2,2-trichloroethoxy) carbonyl-10-deacetylbaccatin are synthesized from baccatin and 10-deacetylbacctin respectively in presence of 2,2,2-trichloroethoxy chloroformate and organic base.
- the preferred bases are pyridine, 4-dimethylaminopyridine or imidazole or like. The most preferred base is pyridine.
- the 3-(prop-2-ynyloxy) carbonyl-2,2-di methyl-4-phenyl-5 oxazolidine carboxylic acid 16 is converted into taxane ester 18 in presence of taxane alcohol such as 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin 17 and condensing agent, preferably dicyclohexylcarbodiimde and organic base preferably 4-dimethylaminopyridine.
- taxane alcohol such as 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin 17 and condensing agent, preferably dicyclohexylcarbodiimde and organic base preferably 4-dimethylaminopyridine.
- This process can also be used to prepare various taxane esters 10 contemplated within the present invention from various 3-(alk-2-ynyloxy) carbonyl-5oxazolidine carboxylic acids and taxane alcohols.
- the opening of the oxazolidine ring in ester 18 is effected by removal of prop-2-ynyloxy carbonyl with ammonium tetrathiomolybadate preferably benzyltriethyl ammonium tetrathiomolybadate which is prepared according to the known procedure described in Syn.Comm., 22(22), 3277-3284(1992).
- the removal of prop-2-ynyloxycarbonyl group is effected by exposing the mixture of ester and acetonitrile to ultrasound for 1-6 hr, most preferably for 3 hr.
- the reaction mixture is diluted with dichloromethane and then washed with water. Removal of the solvents gives the intermediate 19, free amine.
- the same procedure can be applied to prepare other free amino taxane intermediates 11 (where W is hydrogen) contemplated within the present invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a novel oxazolidine carboxylic acid and a process for its preparation. The invention further relates to a process for the preparaton of paclitaxel (taxol) using such oxazolidine carboxylic acid. Paclitaxel (Taxol) (1) is a terpene of taxane family and has the formula shown below and has an application for treatment of various types of cancer. Non-natural analog of paclitaxel (taxol), docetaxel (taxotere) (2) is also an approved anticancer drug. Thus, there is great interest in molecules having similar structures for development of new anticancer drugs and SAR studies.
- 1. Taxol R1=H, R2=Ac, R3=
- 2. Taxotere R1=R2=H, R3=
-
- 4. 10-Deacetylbacctin (DAB) R1=R2=R3=H
- The structure of paclitaxel (taxol) has two distinct unts. One is baccatin (3) and other is N-benzoylphenylisoserine, the side chain, connected to baccatin at C-13 through ester linkage. It has been shown that the -amido- -hydroxy ester side chain at C-13 is very essential for anticancer activity of taxol and any other taxol analogs. The supply of taxol from natural sources is very limited and so there is great interest in its synthesis. 10-deacetyl baccatin (4) is more readily available than taxol from the leaves of yew tree and comprises a starting material for semisynthesis of taxol and taxol analogs. It is known in the literature that it is very difficult to esterify 13 hydroxy of bacctin with -amido- -hydroxy carboxylic acid. The difficulty has been ascribed to spatial disposition of 13 hydroxy in the baccatin nucleus. Therefore, considerable efforts have been made to find precursors of -amido- -hydroxy carboxylic acid which can be coupled with bacctin in high yield and the resultant couple product can be processed to afford 13-O-(-amido- -hydroxycarbonyl) baccatin in high yield and purity.
-
- In the literature, various protecting groups, R1, are described in oxazolidinecarboxylic acid (5). However, alk-2-ynyloxycarbonyl group have not been described so far. The utility of this group over other commonly used protecting groups lies in the fact that this group can be cleaved under neutral condition. All other known protecting groups (R1) are cleaved under either acidic conditions or by hydrogenolysis. The subsequent cleavage of protecting groups R2 and R3 are normally very fast, once R1 is cleaved. Since the baccatin part of taxol is very prone to degradation even under mild acidic or basic conditions, removal of alk-2-ynyloxycarbonyl group under neutral condition facilitates the conversion of taxol intermediate such as 10 to taxol in high yield and high purity.
- An object of this invention is to propose a novel oxazolidine carboxylic acid and a process for the preparation thereof.
- Another object of this invention is to propose oxazolidine carboxylic acid which can advantageously be used in the preparation of anticancer drugs.
- Still another object of this invention is to propose a process for the preparation of taxol and its synthetic analogs using the proposed oxazolidine carboxylic acid.
-
- and wherein R1 is hydrogen, aryl, heteroaryl, alkyl, alkenyl, alkynyl, R2 and R3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl;
- R is hydrogen, alkyl, alkenyl, alkynyl, aryl, substituted aryl, heteroaryl.
- R5 and R6 independently selected from hydrogen, alkyl, alkenyl, alkynyl, arly, heteroaryl, alkoxy, alkeyloxy, alkynyloxy, aryloxy, heteroaryloxy.
- The oxazoldine alkyl groups either alone or with the variable substituents defined above are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like. The alkyl part of alkoxy groups defined above are same as a alkyl groups.
- The oxazoldine alkenyl groups either alone or with the various substituents defined above are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl, hexenyl, and the like. The alkenyl part of alkenyloxy groups defined above are same as a alkenyl groups.
- The oxazoldine alknyl groups, either along or with the various substituents defined above are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethynyl, propynyl, butynyl, isobutynyl, pentynyl, hexynyl and the like. The alkynyl part of alkynyloxy groups defined above are same as alkynyl groups.
- The oxazoldine aryl moieties eiher alone or with various substituents contain from 6 to 10 carbon atoms and include pheny, -naphthyl etc. substituents include alkanoxy, hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino; amido etc.
- As defined herein, the term aryloxy includes aromatic heterocyclic moieties the term aryl includes any compound having an aromatic ring of which no hetero atom is a member, and the term heteroaryl includes any compound having an aromatic ring which comprises a hetero atom.
-
- The present invention also describes process of preparation of 3-(alk-2-ynyloxy)carbonyl-5-oxazolidine carboxylic acid and its analogs.
-
- wherein
- A and B are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy aryloyloxy or;
- A and B together form an oxo;
- L and D are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy;
- E and F are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy aryloyloxy; or E and F together form an oxo;
- G is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or;
- G and M together form an oxo or methylene or oxirane ring or
- M and F together form an oxetane ring;
- J is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or
- I is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy; or
- I and J together form an oxo; and
- K is hydrogen or hydroxy, lower alkoxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy
- P and Q are independently hydrogen or hydroxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy or P and Q together form an oxo; and
- S and T are independently hydrogen, lower alkyl, alkoxy, alkenyl, alkynyl, aryl, aryloxy, substituted aryl or substituted aryloxy; and
- U and V are independently hydrogen or lower alkyl, alkenyl, alkynyl, aryl or substituted aryl or heteroaryl and
- W and W′ are independently hydrogen or lower alkyl, aryl or substituted aryl; and
- Y is hydrogen or lower alkyl, aryl or substituted aryl.
-
- wherein
- A and B are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, or;
- A and B together form an oxo;
- L and D are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy;
- E and F are independently hydrogen or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy; or E and F together form an oxo;
- G is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or;
- G and M together form an oxo or methylene or oxirane ring or M and F together form an oxetane ring;
- J is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy or
- I is hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy; or
- I and J together form an oxo; and
- K is hydrogen or hydroxy, lower alkoxy, alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy
- P and Q are independently hydrogen or hydroxy or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, aryloyloxy or alkoxycarbonyloxy, aryloxycarbonyloxy or alkylsilyloxy
- P and Q together form an oxo; and
- S and T are independently hydroxy, alkoxy, aryloxy, or lower alkanoyloxy, alkenoyloxy, alkynoyloxy, or aryloyloxy; and
- U and V are independently hydrogen or lower alkyl, alkenyl, alkynyl, aryl or substituted aryl or heteroaryl and
- W is hydrogen, alkanoyl, alkenoyl, alkynoyl, aryloyl, heteroaryloyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl.
- The taxol alkyl groups either alone or with the variable substituents defined above are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl and the like. The taxol -alkenyl groups either alone or with the various substituents defined above are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, pentenyl hexenyl, and the like.
- The taxol alkynyl groups, either along or with the various substituents defined above are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 10 carbon atoms. They may be straight chain and include ethynyl, propynyl, butynyl, isobutynyl, pentynyl hexynyl and the like.
- Exemplary alkanoyloxy include acetate, propionate, butyrate, valarate, isobutyrate and the like, the more preferred alkanoyloxy is acetate.
- The taxol aryl moieties either alone or with various substituents contain from 6 to 10 carbon atoms and include phenyl, -naphthyl etc. Substituents include alkanoxy, hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino; amido etc. phenyl is the more preferred aryl.
- As defined herein, the term aryloyloxy includes aromatic heterocyclic moieties, the term aryl includes any compound having an aromatic ring of which no hetero atom is a member, and the term heteroaryl includes any compound having an aromatic ring which comprises a hetero atom.
- Preferred values of the substituents A, B, D, L, E, F, G, M, I, J, K, P, Q, S, T, U, V, W, X and Y are enumerated below in Table-1
A and B A = H A = OAc A = B = H together B = OAc B = H Form an oxo D = OH D = H D = OCOOC D = H D = OCOR D = L = H L = H L = OH H2CCl3 L = OCOOCH2 L = H L = H CCl3 E = H E = OAc E and F E = H F = OAc F = H together F = O form (oxetane) an oxo G AND G = CH2 G = O G and M G = OAc G = H M = CH2 M = O M = CH together M = CH2O M = CH2O (Epoxide) (Epoxide) form an (Oxetane) (Oxetane) oxo I = J = O I = J = H I = OCOPh I = OCOR J = H J = H K = H K = OH K = OCOR K = OCOR P = OH P = H P = OCOCH2 P = H P = OCOR P = Q = H Q = H Q = OH CCl3 Q = OCOCH2 Q = H Q = H CCl3 S = T = CH3 S = H S = H S = OR S = OH S = H T = Ar T = OR T = H T = H T = OH U = Ar U = H V = H V = Ar Structure-10 W = H W = CH3 W = H W = CH3 W = Ar W = H W′ = H W′ = CH3 W′ = CH3 W′ = H W′ = H W′ = Ar Strucutre-11 W = H W = CH3 W = COAr W = COOt Bu Structure-10 Y = H Y = CH3 Y—Ar -
- In this process, isoserine 12 is the starting material. In the preferred starting material, R is aryl and the most preferred R is phenyl. The arylisoserine has two asymmetric carbons, all optically active forms such as enantiomers, diastereomers, racemic mixtures and other mixtures are contemplated here. The preferred optically active form of pheneylisoserine is 2R, 3S. This phenylisoserine is commercially available.
- Thus, phenylisoserine is condensed with alk-2-ynyl haloformate in presence of some base such as alkali hydroxide or carbonate or bicarbonate or any other acid neutralising chemical. Herein, alk-2-ynyl groups, either alone or with the various substitutents defined above are preferably lower alk-2-ynyl containing from three to six carbon atoms in the principal chain and up to 10 carbon atoms and include but-2-ynyl, pent-2-ynyl, prop-2 ynyl, hex-2-ynyl and the like.
- The most preferred haloformate is prop-2-ynyl chloroformate which is available commercially. This can be prepared from diphosgene/triphosgene and propargyl alcohol following the procedure given in Helv.Chim.Acta. Vol 77, 561, 1994.
- The most preferred base here is sodium bicarbonate. The condensation is carried out by addition of chloroformate into a solution of isoserine in aqueous bicarbonate over a period of 5-30 min, most preferably over 10-15 min. The acidification of the reaction mixture affords the N-(alk -2-ynyloxy)carbonylisoserine 13. The most preferred one is where R1 is phenyl, R2, R3, and R4 are hydrogen.
- N-(Alk-2-ynyloxy)carbonylisoserine is then converted into corresponding ester in presence of an alcohol and an activating agent such as dicyclohexylcarbodiimide or carbonyldiimidazole. The most preferred alcohol is methanol and the most preferred activating agents is carbonyldiimidazole. The esterification can be carried out in various solvents such as dichloromethane, chloroform, ethyl acetate, tetrahydrofuran, acetonitrile or dimethylformamide. The most preferred solvent is acetonitrile. The esterification is carried out by first mixing acid with activating agent for 0.5-6 hr, most preferably for 1 hr, at 0-25° C., most preferably at 10° C. Then the alcohol is introduced in the mixture over a period of 10-60 min, most preferably over 30 min and the mixing is done for 1-6 hr, most preferably for 2 hr.
- Methyl ester is alternatively prepared by condensing isoserine with diazomethane. The ethereal solution of diazomethane is prepared from following the standard procedure described in Vogel's Text book of Practical Organic Chemistry, 1989, page 432. The methylation is effected by mixing the solution ofN-(alk-2-ynyloxy)carbonylisoserine in tetrahydrofuran with excess ethereal solution of diazomethane. The resultant mixture is stored for 1-6 hr, most preferably for 2 hr at 5-25° C., most preferably at 10° C., for complete reaction.
- In the most preferred ester 14, R1 is phenyl, R2, R3 and R4 are hydrogen; and R is methyl.
- N-(alk-2-ynyloxy) carbonylisoserine ester 14 is converted into oxazolidine 15 in presence of chemical such as alkoxyalkene or gem-dialkoxyalkane or 1,1,1-trialkoxyalkane. These chemicals are basically reagents for protection of vicinal functional groups such as diols or amino/amidoalchohols in cyclic form. The appropriate chemical is chosen on the basis of type of protecting group required. The most preferred alkoxylalkene, 2-methoxypropene, is available commercially. The reactions are catalysed by p-arylsulfonic acid or their pyridinium salt. The most preferred catalyst is pyridinium p-toluenesulfonate. The protection with 2-methoxypropene results in formation of 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic ester 15. In the most preferred oxazolidine ester, R1, R2 and R3 are hydrogen, R4 is phenyl; R5, R6 and R7 are methyl.
- 3-(Alk-2-ynyloxy) carbonyl-5oxazolidine carboxylic ester is finally converted into corresponding acid by hydrolysis with alkali hydroxide or carbonate and mineral acid used successively. The hydrolysis is effected by mixing of a solution of ester in alcohol with an Aq. alkali hydroxide. The most preferred alcohol is methanol and the most preferred alkali hydroxide is sodium hydroxide. The mixing is done for 1 to 6 hr, the most preferably for 3 hr. After the hydrolysis is over, the reaction mixture is acidified to pH 3-6, most preferably 4.5. The acid 16 is isolated by extraction with dichloromethane. In the most preferred acid, R1, R2, and R3 are hydrogen, R4 is phenyl; R5 and R6 are methyl.
-
- The most preferred 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic is 3-(prop-2-ynyloxy) carbonyl-2,2-di methyl-4-phenyl-5-oxazolidine carboxylic acid. The preferred tetracyclic taxane alcohols are 7-O-triethylsilylbaccatin, 7-O-(2,2,2-trichloro-ethoxy) carbonylbaccatin, 7,10-di-O-(2,2,2-trichloroethoxy) carbonyl-10-deacetylbaccatin, 7, 10-di-O-benzyloxycarbonyl-10-deacetyl baccatin, 7-O-t-butyloxycarbonylbaccatin, 7, 10-di-O-t-butyloxycarbonyl-10-deacetylbaccatin, 7-O-(prop-2-ynyloxy) carbonyl baccatin, and 7,10-di-O-(prop-2-ynyloxy) carbonyl-10-deacetyl baccatin. The most preferred alcohols are 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin, 7,10-di-O-(2,2,2-trichloroethoxy) carbonyl-10-deacetylbaccatin.
- 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin, 7,10-di-O-(2,2,2-trichloroethoxy) carbonyl-10-deacetylbaccatin are synthesized from baccatin and 10-deacetylbacctin respectively in presence of 2,2,2-trichloroethoxy chloroformate and organic base. The preferred bases are pyridine, 4-dimethylaminopyridine or imidazole or like. The most preferred base is pyridine.
- The 3-(prop-2-ynyloxy) carbonyl-2,2-di methyl-4-phenyl-5 oxazolidine carboxylic acid 16 is converted into taxane ester 18 in presence of taxane alcohol such as 7-O-(2,2,2-trichloroethoxy) carbonylbaccatin 17 and condensing agent, preferably dicyclohexylcarbodiimde and organic base preferably 4-dimethylaminopyridine. This process can also be used to prepare various taxane esters 10 contemplated within the present invention from various 3-(alk-2-ynyloxy) carbonyl-5oxazolidine carboxylic acids and taxane alcohols.
- The opening of the oxazolidine ring in ester 18 is effected by removal of prop-2-ynyloxy carbonyl with ammonium tetrathiomolybadate preferably benzyltriethyl ammonium tetrathiomolybadate which is prepared according to the known procedure described in Syn.Comm., 22(22), 3277-3284(1992). The removal of prop-2-ynyloxycarbonyl group is effected by exposing the mixture of ester and acetonitrile to ultrasound for 1-6 hr, most preferably for 3 hr. The reaction mixture is diluted with dichloromethane and then washed with water. Removal of the solvents gives the intermediate 19, free amine. The same procedure can be applied to prepare other free amino taxane intermediates 11 (where W is hydrogen) contemplated within the present invention.
-
- The invention Will now be explained in greater details with the help of the accompanying examples:
- (2R, 3S) phenylisoserine (25 gm, 0.138 mole) was dissolved in sodium bicarbonate and potassium bicarbonate (2.5 L) and then 0-5° C. Prop-2-ynyl chloroformate (25 gm, 0.21 mmol) was added drop wise into the solution in a period of 10 to 15 mins. After complete addition the reaction mixture was stirred for 6 Hrs at 05° C. pH of the solution was brought down to 4 by drop wise addition of 10% hydrochloric acid, at temperature 5-6° C. The acidified aqueous layer was extracted with a mixture of tetrahydrofuran and dichloromethane (4:1, 3×1 L). The combined organic layer was washed with water until the neutral pH.
- The organic layer was dried over sodium sulphate and filtered evaporated in under vacuum below 140° C. The residue was dried in vacuum until constant weight to yield 20 g of compound 13.
- To a ice cooled solution of Comp-13 (20 g, 76 mmol) in tetrahydrofuran (500 ml) was added drop wise a saturated ethereal solution of diazomethane. The addition was continued until the colour of diazomethane persists. Stirring was continued for further 2 Hrs. The excess diazomethane was removed by drop wise addition of acetic acid. The reaction mixture was then washed with 7 solution of sodium bicarbonate. The organic layer was washed with brine and dried over sodium sulfate. The organic layer was filtered and evaporated. The crude product was purified over silica gel (230-400) (eluent; hexane-ethyl acetate, 7:3 to 1:1) yield comp-14 (18 gm).
- To a stirred solution of Comp 13 (5.0 g, 19 mmol) in tetrahydrofuran (50 ml) was added 1,1 carbonyl diimidazole (6.2 gm, 38 mmol) at 0-10° C. The stirring was continued for further 1 Hr. Methanol (3.2 ml) was then added drop wise into the solution in a period of 30 min. After complete addition, the reaction mixture was stirred for 2 Hr, when T.L.C. indicated completion of the reaction. The reaction mixture was concentrated and the residue dissolved in ethyl acetate (2×100 ml), washed with 5% hydrochloric acid, water and brine. The organic layer was dried and evaporated. The crude product was chromatograph over silica gel (eluent hexane:ethyl acetate 7:3 to 1:1) yield to comp 14 (4.5 gm).
- To a stirred solution of Comp-14 (5 g 18 mmol) in toluene (180 ml) was added 2-methoxypropene (35 ml, 0.36 mole), and pyridinium p-toluenesulfonate (425 mg). The mixture was stirred at 25° C. for 10-15 min and then heated 80° C. for 6 Hr. Progress of the reaction was checked by T.L.C. After completion, the reaction, mixture was cooled and diluted with ethyl acetate (300 ml). The organic layer was washed with 5% sodium bicarbonate (2×125 ml) then with brine (150 ml). The organic layer was dried over sodium sulfate. After filtration, the organic layer was evaporated in rotavapour under vacuum below 40° C. The crude product was purified by column chromatography over silica gel, 240-400 mesh (eluent lower 85:15 hexane and ethyl acetate to yield comp-15, (3 g) as a colourless oil.
- To a stirred solution of comp-15 (3.5 g, 11 mmol) in methanol (35 ml) was added a solution of lithium hydroxide (1.8 g) in water (15 ml). After stirring at 20-25° C. for 3 Hr (absence of starting material, was checked by T.L.C.). The reaction mixture was concentrated to reduce the volume to 15 ml and diluted with dichloromethane (200 ml). The mixture was then washed with water (250 ml). The aqueous layer was separated and cooled to 5-15° C. and solution pH was brought to 4 by adding 10% hydrochloric acid. The aqueous layer was extracted with dichloromethane (3×300 ml). The combined organic layer was washed with brine and dried over, preferably sodium sulfate and magnesium sulfate. After filtration the organic layer was evaporated under vaccum and residue was dried up to constant weight to yield compound-16 (2.2 gm).
- To a stirred solution of comp-16 (2.0 g, 6.6 mmol) in toluene or (20 ml) was added dicyclohexylcarbodimide (3 g) followed by addition of 7-O-trichloroethoxycarbonylbaccatin 17, (2 g, 2.62 mmol) and DMAP (101 mg). The stirring was continued for 1 Hr. The reaction mixture was diluted with ethyl acetate (100 ml) and filtered. The filtrate was washed successively with aqueous saturated sodium bicarbonate and brine. The organic layer was dried and evaporated under vaccum. The crude product was purified over silica gel (eluent 4:1 hexane and ethyl acetate) to yield comp-18 (1.9 g).
- A mixture of comp-18 (2 g, 1.91 mmol) and benzyl triethylammonium tetrathiomolybedate (1.16 g) in acetonitrile (5 ml) was kept in ultrasound bath for 4 hr and then diluted with dichloromethane (30 ml). The mixture was washed with water (2×10 mL). The organic layer was evaporated to give comp-19 (1.75 g) as solid.
- A mixture of comp-19 (1 g, 1.08 mmol) in ethyl acetate (5 mL) and saturated Aq. sodium bicarbonate (3 mL) was added benzoyl chloride (0.17 mL) in ethyl acetate (2 mL) drop wise at 0° C. After, the complete addition, the temperature was raised to 25° C. and the stirring was continued for further 2 hr. The Aq. layer was separated and the organic layer was washed with water until neutral. The organic layer was dried over sodium sulfate and then evaporated to give a solid. A mixture of this solid, acetic acid (10 mL), methanol (5 mL) and zinc powder (1 g) was heated to 60° C. with stirring. After 1 hr, the reaction mixture was cooled and then filtered. The filtrate was evaporated. The residue was dissolved in ethyl acetate and then washed with Aq. sodium bicarbonate, water and brine. The organic layer was dried over sodium sulfate, then filtered and evaporated. The solid residue was crystallised with acetone-hexane then with methanol-water to afford Taxol (0.74 g, yield 80% from comp-18 99% HPLC w/w assay, 99% HPLC chromatographic purity).
Claims (21)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000020 WO2002066448A1 (en) | 2001-02-20 | 2001-02-20 | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid |
US09/870,942 US6506905B1 (en) | 2001-02-20 | 2001-06-01 | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000020 WO2002066448A1 (en) | 2001-02-20 | 2001-02-20 | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid |
US09/870,942 US6506905B1 (en) | 2001-02-20 | 2001-06-01 | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
US6506905B1 US6506905B1 (en) | 2003-01-14 |
US20030013888A1 true US20030013888A1 (en) | 2003-01-16 |
Family
ID=26324104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/870,942 Expired - Fee Related US6506905B1 (en) | 2001-02-20 | 2001-06-01 | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid |
Country Status (2)
Country | Link |
---|---|
US (1) | US6506905B1 (en) |
WO (1) | WO2002066448A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6891050B2 (en) * | 2001-08-10 | 2005-05-10 | Dabur India Limited | Process for the preparation of taxanes such as paclitaxel, docetaxel and structurally similar analogs |
US6881852B2 (en) | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
US7247738B2 (en) * | 2002-05-07 | 2007-07-24 | Dabur India Limited | Method of preparation of anticancer taxanes using 3-[(substituted-2-trialkylsilyl) ethoxycarbonyl]-5-oxazolidine carboxylic acids |
US6900342B2 (en) * | 2002-05-10 | 2005-05-31 | Dabur India Limited | Anticancer taxanes such as paclitaxel, docetaxel and their structural analogs, and a method for the preparation thereof |
US6838569B2 (en) * | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2687151B1 (en) * | 1992-02-07 | 1994-03-25 | Rhone Poulenc Rorer Sa | NOVEL DERIVATIVES OF BACCATIN III AND DESACETYL-10 BACCATIN III, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
FR2696459B1 (en) * | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for the preparation of taxane derivatives. |
FR2698361B1 (en) * | 1992-11-20 | 1995-01-13 | Rhone Poulenc Rorer Sa | Process for the preparation of an oxazolidine-1,3 carboxylic-5 acid. |
FR2732968B1 (en) * | 1995-04-14 | 1997-05-16 | Rhone Poulenc Rorer Sa | NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
FR2740451B1 (en) * | 1995-10-27 | 1998-01-16 | Seripharm | NOVEL INTERMEDIATES FOR THE HEMISYNTHESIS OF TAXANES, THEIR PREPARATION METHODS AND THEIR USE IN THE GENERAL SYNTHESIS OF TAXANES |
US6150537A (en) * | 1997-12-12 | 2000-11-21 | Emory University | Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents |
-
2001
- 2001-02-20 WO PCT/IN2001/000020 patent/WO2002066448A1/en active IP Right Grant
- 2001-06-01 US US09/870,942 patent/US6506905B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6506905B1 (en) | 2003-01-14 |
WO2002066448A1 (en) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0663905B1 (en) | Novel method of esterification of baccatine iii an 10-deacetylbaccatine iii | |
RU2033994C1 (en) | Oxazinone and a method of taxol synthesis | |
JP2500198B2 (en) | New β-lactam | |
JP3394284B2 (en) | Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones | |
EP0663906B1 (en) | Method of preparing taxane derivatives | |
US5015744A (en) | Method for preparation of taxol using an oxazinone | |
US20010037020A1 (en) | Method for preparation of taxol | |
CA2148103C (en) | Process for preparing taxane derivatives | |
FR2688499A1 (en) | PROCESS FOR THE PREPARATION OF BETA-PHENYLISOSERINE AND ITS ANALOGS. | |
US6506905B1 (en) | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid | |
KR100545436B1 (en) | Intermediates useful for the semisynthesis of paclitaxel and its homologues and preparation methods thereof | |
KR100225535B1 (en) | Manufacturing method of paclitaxel | |
RU2326876C2 (en) | Method of paclitaxel preparation | |
EP1370541B1 (en) | Method of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid | |
AU2001246805A1 (en) | Method of preparation of paclitaxel (Taxol) using 3-(alk-2-ynyloxy) carbonyl-5-oxazolidine carboxylic acid | |
PL169285B1 (en) | Method of obtaining a-delta-amido ester | |
KR19990069272A (en) | (3R, 4S) -3-hydroxy-4-phenylazetidin-2-one and its intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DABUR INDIA LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRAKASH, SHARMA ARUN;SUBRATA, SARKAR;REEL/FRAME:012186/0889 Effective date: 20010827 |
|
AS | Assignment |
Owner name: DABUR INDIA LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHARMA, ARUN PRAKASH;SARKAR, SUBRATA;REEL/FRAME:013192/0628 Effective date: 20020729 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: DABUR PHARMA LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DABUR INDIA LIMITED;REEL/FRAME:025204/0667 Effective date: 20081106 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150114 |